The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Indeed, as I understand it as an amateur, N4P are flogging a large number of very spiky sand particles that are excellent at transferring biological material to a target without it getting broken down by the body in the bloodstream. Happy to be corrected, but that is my very basic understanding of it.
Whatever happened to the in-vitro re-tests they were doing at University Of Queensland BTW? These seem to have been forgotten. I know they had problems originally and had to get the lab set up correctly so the in-vitro results could be repeated.
I meant in-vivo re-tests.
Those in vivo studies went ahead and the results were rns’ed 20/08/19.
The results were very promising using both 2 &3 injections.
They have since decided that a more monodisperse solution (all particles of a similar size) will result in less agglomeration (particles sticking together) and would make it much more likely to get better In vivo results using only one injection.
The dispersion / agglomeration works have been ongoing and should be completed very soon.
All looking good.
Proof of concept stage 3 already on going and Nigel already hints that his invitation for a collaboration with companies who are already at advanced stage with Vaccine for covid19 to look at Nuvec as a delivery system..i am sure the discussion is on behind us...the race is on for the vaccine and delivery system to compliment. N4 p shares are already being rerated in anticipation..imo..will not be surprised if we move to last week's high of 15p plus..
Hope we are also considering Oral delivery system using Nuvec with our concept studies stage 3 as Vaxart in Califorinia has submitted phase 1 of MIT to FDA whose share is trading at $10... can Leister, John or anyone can tell us whether our concept can covert to Oral delivery system using Nuvec methodology???
From 06/07 rns it looks like the investigations into the oral applications are currently at the in-vitro phase Maz:
'To that end the Company will working with Evotec to undertake some preliminary in vitro studies to establish first that Nuvec® can be optimised to transfect murine intestinal cells and, secondly, that it can transfect human gastrointestinal mucosal/epithelial cells. Without being able to efficiently transfect gut cells, any oral application would not be possible, so it is essential to complete these studies prior to progressing any further with this initiative.'
Assuming this study was started immediately, we could be approx 45 days into these works so news could come at any time on this.
Also awaiting further updates on:
viral vector manufacturing
the pre in-vivo study
Dispersion / agglomeration works
Ongoing potential commercial partner discussions
All the above have the potential to be transformational....Great time to be in here. I'm sure i've missed items out so please add them on.
John thank u for your valuable input and knowledge on this subject and now you have put my mind to rest....happy days in front of us
John knows his stuff Maxik! to add to his great post.
The dispersion works hold very few restrictions to the oral applications as any agglomeration forming when the particles collide and stick together Is less of an issue when transfecting gut cells. Evotec are again doing these in-vitro studies and it’s been said There is not a significant cost to the company.
I’m definitely happy to be invested and will be pleased to see the updates as they come through.
I’m guessing there’s people that want in at a lower price.. Get in, hold tight and bet chuffed you’ve got in at the pre-clinical stage. Once a partner is onboard we’ll be seeing SNG, AVCT, NCYT style chart movements.
Leister it looks like we are all in the same page on success of Nuvec...thanks for your input...GLA